Tag Archives: healthcare

Biopharmaceuticals and Accountable Care Organizations: Balancing Cost and Quality

Biopharmaceuticals and Accountable Care Organizations: Balancing Cost and Quality

As biopharmaceutical manufacturers consider the new reality of accountable care organizations (ACOs) and the impact on their businesses, they must be ready to demonstrate the value of their products in ways that recognize the fine balance of cost and quality that ACO and ACO-like models seek to achieve. According to panelists speaking at the 2013 BIO International Convention session entitled, “Accountable Care Organization (ACO) Framework for Biopharmaceuticals,” there are three primary considerations when it comes Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

The Affordable Care Act is Here to Stay

The Affordable Care Act is Here to Stay

The Patient Protection and Affordable Care Act (ACA) of 2010 includes provisions that could lead to new and improved treatments, cures and cost savings for patients. All of these changes, however, will impact the biotechnology industry and the future of patient access to needed medicines. In an expert panel at the 2013 BIO International Convention moderated by BioCentury’s Steve Usdin, multiple stakeholders addressed key elements of the ACA focused on both the value the ACA Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

The Rise of Specialty Pharmaceuticals

Albert Thigpen

Fact: Specialty pharmaceuticals represented nearly 25 percent of all drug spending last year. By 2018, it’s estimated they’ll account for nearly half of the 100 top-selling medications on the market. With an average cost for a specialty medical therapy hovering around $35,000 to $75,000 per patient per year, this is an area that is getting the attention of top industry players – from biopharma who see the market opportunity to healthcare payors like health plans Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

The Ethics of the Market Access Debate

Rogerio Vivaldi

At the core of the market access conversation lies the question of value. How much do we value two years added to the end of an 80-year-old’s life? How do we put a dollar amount on a medicine that prevents a rare disease patient, who may only live to age 20 regardless of receiving treatment, from losing her ability to walk? How can we define metrics to measure the cost of a child with a Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Managed Entry Trumps Risk Sharing

Since 2000, pharmaceu-tical and biotech companies have engaged in agreements with government and private payers across the world to gain market access for their innovative drugs despite struggles to qualify for formal reimbursement criteria, such as the cost effectiveness threshold from NICE in the UK. These agreements, usually referred to as “risk sharing” agreements, have had a wide variety of structures but usually do not involve any sharing of risk, as the name misleadingly suggests. Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,